Democrats Link Trump's Drug Stock Gains to Medicare Pricing Exemptions

A congressional Democratic report says investments held on President Donald Trump's behalf grew substantially after his return to the White House, including holdings in drugmakers that gained from Medicare negotiation exemptions. The report values his pharmaceutical stock at up to $56.2 million by late 2025, with as much as $39.1 million tied to companies helped by the 2025 tax-and-spending law. The White House rejects conflict-of-interest claims, while the report says the exemptions could raise costs for some Medicare patients needing cancer or other treatments.

EXPANDED:

A Democratic report from the Joint Economic Committee minority says Donald Trump’s drug-company holdings climbed from a 2024 maximum of $1.7 million to as much as $56.2 million by late 2025. It links up to $39.1 million to firms helped by Medicare drug-price negotiation carveouts in a 2025 Republican fiscal law.

The report adds that his